Context Therapeutics Inc. (CNTX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
CNTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Context Therapeutics Inc. (CNTX) trades at a price-to-earnings ratio of -6.1x, with a stock price of $2.33 and trailing twelve-month earnings per share of $-0.42.
Compared to the Healthcare sector median P/E of 22.3x, CNTX trades at a 127% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CNTX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CNTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CNTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $243M | 4.9Lowest | 4.84Best | +49%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See CNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCNTX — Frequently Asked Questions
Quick answers to the most common questions about buying CNTX stock.
Is CNTX stock overvalued or undervalued?
CNTX current P/E: -6.1x. 5-year average P/E: N/A. Percentile: N/A.
How does CNTX's valuation compare to peers?
Context Therapeutics Inc. P/E of -6.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CNTX's PEG ratio?
CNTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.